Bladder cancer is a disease in which abnormal cells grow in the lining of the bladder, the organ that stores urine. It is one of the most common cancers, and roughly 90% of cases begin in the urothelial cells that line the bladder’s inner surface. When caught early, before it grows into the bladder’s muscle wall, the outlook is favorable, with five-year survival rates above 70% for localized disease.
Types of Bladder Cancer
The vast majority of bladder cancers, about 90%, are urothelial carcinomas (also called transitional cell carcinomas). These start in the stretchy cells that line the inside of the bladder. Squamous cell carcinoma accounts for roughly 3% of cases in the United States and is more common in parts of Africa and the Middle East where a parasitic bladder infection is widespread. Adenocarcinoma, which begins in mucus-producing gland cells, is rarer still.
Beyond the cell type, the most important distinction is whether the cancer has grown into the bladder’s muscle layer. Non-muscle-invasive bladder cancer (stages 0 and I) stays in the inner lining or the connective tissue just beneath it. Muscle-invasive bladder cancer (stage II and above) has penetrated deeper into the bladder wall, which changes both treatment and prognosis significantly.
Symptoms and Early Warning Signs
Blood in the urine is the single most common sign. About 80% of people with bladder cancer first notice visible blood when they urinate. It is typically painless, present throughout the entire stream, and comes and goes, which can be misleading. Some people see blood once, assume it resolved on its own, and delay getting checked.
Around 20% of patients experience irritative bladder symptoms instead of, or alongside, blood in the urine. These include a sudden, strong urge to urinate, needing to go more often than usual, and pain or burning during urination. These symptoms overlap heavily with urinary tract infections and an enlarged prostate, which is one reason bladder cancer can be missed early on. Persistent irritative symptoms that don’t respond to typical UTI treatment deserve further investigation.
Major Risk Factors
Smoking is the single biggest risk factor. Tobacco contains carcinogens that enter the bloodstream, get filtered through the kidneys, and collect in the urine, bathing the bladder lining in harmful chemicals for hours at a time. This repeated exposure damages the DNA in bladder cells and can eventually trigger cancerous growth.
Workplace chemical exposure is the second most significant risk. People who work with paints, dyes, metals, or petroleum products face higher rates of bladder cancer, sometimes decades after their exposure. Other established risk factors include:
- Chronic bladder irritation from long-term catheter use or parasitic infections (particularly Schistosoma haematobium, common in Africa and the Middle East)
- Previous pelvic radiation therapy or treatment with certain chemotherapy drugs
- Arsenic in drinking water, especially from private wells
How Bladder Cancer Is Diagnosed
If blood in the urine or persistent bladder symptoms raise suspicion, the diagnostic process typically starts with a urine sample checked for blood, abnormal cells, or infection. From there, the key test is cystoscopy: a thin, lighted tube is inserted through the urethra so the doctor can visually inspect the bladder lining for anything abnormal. It’s an outpatient procedure, usually done under local anesthesia.
If the doctor spots a suspicious area during cystoscopy, a biopsy is taken at the same time. A small tissue sample, or sometimes the entire visible tumor, is removed and examined under a microscope. This step confirms whether cancer is present and, if so, what type and grade it is. Urine tumor marker tests, which detect substances produced by bladder cancer cells, can also support the diagnosis.
Staging: How Far It Has Spread
Bladder cancer is staged using the TNM system, which evaluates the tumor’s depth, lymph node involvement, and whether it has spread to distant organs. The stages break down practically like this:
- Stage 0: Cancer cells sit only in the innermost lining. They haven’t invaded the bladder wall at all.
- Stage I: Cancer has grown into the connective tissue beneath the lining but hasn’t reached the muscle.
- Stage II: Cancer has reached the muscle layer of the bladder wall. This is the threshold for muscle-invasive disease.
- Stage III and IV: Cancer has spread beyond the bladder wall to nearby tissues, lymph nodes, or distant organs.
Stages 0 and I are considered non-muscle-invasive and are treated very differently from stage II and beyond. About half of all bladder cancers are caught at the earliest “in situ” stage, where cancer is still confined to the originating layer of cells. Another 34% are caught while still localized to the bladder.
Treatment for Early-Stage Disease
Non-muscle-invasive bladder cancer is typically managed by removing visible tumors during cystoscopy, followed by treatment delivered directly into the bladder to reduce the chance of recurrence. The most effective of these treatments uses a weakened form of the tuberculosis vaccine (BCG), which is instilled into the bladder through a catheter and held there for about two hours.
BCG works by triggering a strong immune response inside the bladder. The solution stimulates immune cells to recognize and attack cancer cells along the bladder lining. A standard course involves six weekly treatments, followed by maintenance sessions of three weekly treatments given at intervals over three years, for a total of about 27 instillations. This schedule is intensive, but BCG remains the most effective option for preventing recurrence in intermediate and high-risk non-muscle-invasive cases.
Treatment for Muscle-Invasive Disease
Once cancer has grown into the bladder’s muscle wall, the standard treatment is surgical removal of the entire bladder, called radical cystectomy. This is the most effective approach for muscle-invasive disease, with five-year cancer-specific survival rates up to 76%. The surgery removes the bladder along with surrounding lymph nodes, and chemotherapy is often given before or after the operation.
After bladder removal, a new path for urine must be created. The most common options are:
- Ileal conduit: A short piece of intestine is used to create a channel that carries urine to an opening in the abdomen, where it drains into an external bag. This is the simplest option surgically and is often recommended for older patients or those with other significant health conditions.
- Neobladder: A new bladder-shaped pouch is constructed from intestinal tissue and connected to the urethra, allowing you to urinate somewhat normally. This requires good kidney function and enough physical dexterity to manage potential complications like incomplete emptying.
- Continent cutaneous diversion: An internal pouch is created with a valve to the skin surface, which you drain periodically with a catheter. There’s no external bag, but it requires manual draining several times a day.
Most patients are candidates for all three options. The choice depends on the cancer’s location, your overall health, and your ability to manage each type long-term.
Immunotherapy for Advanced Disease
For bladder cancer that has spread beyond the bladder or returned after chemotherapy, immune checkpoint inhibitors have become a standard treatment. These drugs work by removing a “brake” that cancer cells use to hide from the immune system, allowing your body’s own defenses to recognize and attack the tumor.
Checkpoint inhibitors are approved both for patients whose cancer has progressed after chemotherapy and for those who cannot tolerate platinum-based chemotherapy as a first treatment. Response rates in clinical trials have been roughly 20% to 30% for patients with advanced disease, and when responses do occur, they tend to be durable. For patients whose cancer has progressed after chemotherapy, immunotherapy alone is the current standard of care.
Survival Rates by Stage
Five-year relative survival rates for bladder cancer vary dramatically depending on how far the disease has spread at diagnosis. Based on data from 2015 to 2021:
- In situ (earliest stage): 97.9%
- Localized (confined to the bladder): 72.6%
- Regional (spread to nearby lymph nodes): 40.5%
- Distant (metastatic): 9.1%
These numbers reflect averages across all patients and all treatment types. Individual outcomes depend on the specific cancer grade, your overall health, and how the cancer responds to treatment. The steep drop between localized and regional disease underscores why early detection matters so much.
Why Ongoing Monitoring Is Critical
Bladder cancer has one of the highest recurrence rates of any cancer, particularly for non-muscle-invasive disease. Even after successful treatment, tumors can return in the same spot or in new areas of the bladder lining. This makes regular follow-up cystoscopy essential.
Surveillance schedules are tailored to your risk level. High-risk patients may need cystoscopy every 9 to 11 weeks initially, while lower-risk patients can safely extend intervals to 30 to 40 weeks. Personalized scheduling based on tumor history, grade, and the number of previous recurrences leads to earlier detection of potentially dangerous tumors compared to a one-size-fits-all approach. Many patients continue surveillance cystoscopies for years, and in some cases, indefinitely.